Mangrove Partners IM LLC Makes New $1.15 Million Investment in Establishment Labs Holdings Inc. $ESTA

Mangrove Partners IM LLC bought a new position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 15,834 shares of the company’s stock, valued at approximately $1,154,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Quarry LP acquired a new stake in Establishment Labs in the third quarter worth approximately $34,000. Kestra Advisory Services LLC acquired a new stake in Establishment Labs in the fourth quarter worth approximately $47,000. Osaic Holdings Inc. lifted its position in Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after purchasing an additional 1,800 shares during the period. Truist Financial Corp acquired a new stake in Establishment Labs in the fourth quarter worth approximately $200,000. Finally, PharVision Advisers LLC acquired a new stake in Establishment Labs in the third quarter worth approximately $203,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Establishment Labs Price Performance

NASDAQ ESTA opened at $82.57 on Wednesday. The stock has a market capitalization of $2.43 billion, a P/E ratio of -55.42 and a beta of 1.11. Establishment Labs Holdings Inc. has a 1 year low of $33.35 and a 1 year high of $86.00. The business’s fifty day moving average is $69.81 and its two-hundred day moving average is $69.38. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The company had revenue of $59.88 million during the quarter, compared to the consensus estimate of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. Establishment Labs’s quarterly revenue was up 44.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.70) EPS. On average, research analysts forecast that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current fiscal year.

Insider Transactions at Establishment Labs

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the sale, the director directly owned 927,504 shares of the company’s stock, valued at $69,952,351.68. The trade was a 10.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders have sold 330,000 shares of company stock worth $22,854,538. 9.99% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on ESTA shares. Citigroup restated a “neutral” rating on shares of Establishment Labs in a research report on Wednesday, May 6th. Needham & Company LLC upped their target price on Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Mizuho upped their target price on Establishment Labs from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Canaccord Genuity Group upped their target price on Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, Wall Street Zen downgraded Establishment Labs from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $87.14.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.